<DOC>
	<DOCNO>NCT02220062</DOCNO>
	<brief_summary>Pancreatic cancer relate pain difficult control , even high dos narcotic , whose adverse effect may impair quality life . So EUS-CPN ( endoscopic ultrasound guide celiac plexus neurolysis ) well establish effective technique control pain reduce narcotic requirement patient pancreatic cancer . Recently , celiac ganglion visualize accessed endoscopic ultrasound . So allows direct injection individual celiac ganglion perform celiac ganglion neurolysis . This precise delivery therapeutic drug offer potential enhance efficacy safety . To evaluate hypothesis , randomize controlled trial aim compare efficacy safety EUS-CGN ( Endoscopic ultrasound guide celiac ganglia neurolysis ) v . Bilateral EUS-CPN ( Endoscopic ultrasound guide celiac plexus neurolysis ) provide relief pancreas cancer-related pain .</brief_summary>
	<brief_title>Randomized , Controlled Trial Endoscopic Ultrasound-Guided Bilateral Celiac Plexus Neurolysis v Celiac Ganglia Neurolysis Control Pain Inoperable Pancreatic Cancer Patients With Inadequate Pain Control Pain Killer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . At least 19 year old age ( 70 year old age , need consent legal representative ) 2 . Inoperable pancreatic cancer patient 3 . Pancreatic cancer patient inadequate pain control pain killer ( VAS score 4 point ) 4 . Patient agree participate study 1 . Abnormal clotting ( international normalize ratio ≥1.5 ) 2 . Reduced platelet count ( ≤50000/μL ) 3 . Use anticoagulation agent 4 . Presence gastric and/or esophageal varix 5 . Anatomical deformity due past surgery</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>